Discontinued — last reported Q4 '25
KKR & Co. Interest Paid increased by 10.1% to $719.63M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.1%, from $791.84M to $719.63M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 21.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $326.63M | $260.37M | $365.47M | $329.78M | $387.81M | $395.01M | $387.53M | $566.90M | $662.71M | $729.05M | $732.43M | $745.41M | $736.95M | $662.80M | $791.84M | $602.63M | $685.26M | $653.87M | $719.63M |
| QoQ Change | — | -20.3% | +40.4% | -9.8% | +17.6% | +1.9% | -1.9% | +46.3% | +16.9% | +10.0% | +0.5% | +1.8% | -1.1% | -10.1% | +19.5% | -23.9% | +13.7% | -4.6% | +10.1% |
| YoY Change | — | — | — | — | +18.7% | +51.7% | +6.0% | +71.9% | +70.9% | +84.6% | +89.0% | +31.5% | +11.2% | -9.1% | +8.1% | -19.2% | -7.0% | -1.3% | -9.1% |